SKP2 overexpression is associated with increased serine 10 Phosphorylation of p27 (pSer10p27) in triple-negative breast cancer

Journal of Cellular Physiology

Volumn 229, Issue 9, 2014, Pages 1160-1169

  Fagan Solis, Katerina D ^a   Pentecost, Brian T ^b   Gozgit, Joseph M ^a   Bentley, Brooke A ^c   Marconi, Sharon M ^c   Otis, Christopher N ^c   Anderton, Douglas L ^d   Schneider, Sallie Smith ^e   Arcaro, Kathleen F ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b WADSWORTH CENTER   (United States)

^c BAYSTATE MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

^e Pioneer Valley Life Sciences Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; ESTROGEN RECEPTOR; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; SERINE;

ARTICLE; BENIGN TUMOR; BREAST CANCER CELL LINE; BREAST CARCINOMA; BREAST REDUCTION; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; JURISPRUDENCE; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CELL CYCLE; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PHOSPHORYLATION; RNA INTERFERENCE; S-PHASE KINASE-ASSOCIATED PROTEINS; SERINE; SIGNAL TRANSDUCTION; TRANSFECTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84901207645     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24545     Document Type: Article

References (53)

1. American Cancer Society. 2012. Cancer facts & figures 2012.
2. Arakawa-Takeuchi S, Kobayashi K, Park JH, Uranbileg B, Yamamoto H, Jinno S, Okayama H. 2010. Mammalian target of rapamycin complex 1 signaling opposes the effects of anchorage loss leading to activation of CDK4 and CDC6 stabilization. FEBS Lett 584:2779-2785.
3. Bast RC, Jr., Ravdin P, Hayes DF, Bates S, Fritsche H, Jr., Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. 2001. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878.
4. Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. 2006. A pathway in quiescent cells that controls p27KIP1 stability, subcellular localization, and tumor suppression. Genes Dev 20:47-64.
5. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, Nabel EG. 2002. A growth factor-dependent nuclear kinase phosphorylates p27(KIP1) and regulates cell cycle progression. EMBO J 21:3390-3401.
6. Carrano AC, Eytan E, Hershko A, Pagano M. 1999. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1:193-199.
7. Chan CH, Lee SW, Wang J, Lin HK. 2010. Regulation of SKP2 expression and activity and its role in cancer progression. Sci World J 10:1001-1015.
8. Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, Logothetis CJ, Hung MC, Zhang S, Lin HK. 2013. Pharmacological inactivation of SKP2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154:556-568.
9. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. 2008. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368-1376.
10. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ. 2008. Targeting the p27 E3 ligase SCF(SKP2) results in p27- and SKP2-mediated cell-cycle arrest and activation of autophagy. Blood 111:4690-4699.
11. Chiappetta G, De Marco C, Quintiero A, Califano D, Gherardi S, Malanga D, Scrima M, Montero-Conde C, Cito L, Monaco M, Motti ML, Pasquinelli R, Agosti V, Robledo M, Fusco A, Viglietto G. 2007. Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocr Relat Cancer 14:405-420.
12. Davidovich S, Ben-Izhak O, Shapira M, Futerman B, Hershko DD. 2008. Over-expression of SKP2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer. Breast Cancer Res 10:R63.
13. Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E. 2004. The cyclin-dependent kinase inhibitor p27KIP1 is stabilized in G(0) by MIRK/DYRK1B kinase. J Biol Chem 279:22498-22504.
14. Dickson RB, Lippman ME. 1995. Growth factors in breast cancer. Endocr Rev 16:559-589.
15. Dow R, Hendley J, Pirkmaier A, Musgrove EA, Germain D. 2001. Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein SKP2. J Biol Chem 276:45945-45951.
16. Fagan-Solis KD, Schneider SS, Pentecost BT, Bentley BA, Otis CN, Gierthy JF, Arcaro KF. 2013. The RhoA pathway mediates MMP-2 and MMP-9-independent invasive behavior in a triple-negative breast cancer cell line. J Cell Biochem 114:1385-1394.
17. Foulkes WD, Smith IE, Reis-Filho JS. 2010. Triple-negative breast cancer. N Engl J Med 363:1938-1948.
18. Fujita T, Liu W, Doihara H, Date H, Wan Y. 2008. Dissection of the APCCdh1-SKP2 cascade in breast cancer. Clin Cancer Res 14:1966-1975.
19. Gozgit JM, Pentecost BT, Marconi SA, Otis CN, Wu C, Arcaro KF. 2006. Use of an aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer. Mol Cancer Res 4:905-913.
20. Gozgit JM, Pentecost BT, Marconi SA, Ricketts-Loriaux RS, Otis CN, Arcaro KF. 2007. PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-AKT-negative breast carcinomas. Br J Cancer 97:809-817.
21. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W. 2001. SKP2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 98:5043-5048.
22. Hammond MEH, Hayes DF, Wolff AC, Mangu PB, Tamin S. 2010. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 27:2784-2795.
23. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
24. He W, Wang X, Chen L, Guan X. 2012. A crosstalk imbalance between p27kip1 and its interacting molecules enhances breast carcinogenesis. Cancer Biother Radiopharm 27:399-402.
25. Huang HC, Way TD, Lin CL, Lin JK. 2008. EGCG stabilizes p27KIP1 in E2-stimulated MCF-7 cells through down-regulation of the SKP2 protein. Endocrinology 149:5972-5983.
26. Huang HC, Lin CL, Lin JK. 2011. 1, 2, 3, 4, 6-penta-O-galloyl-beta-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of SKP2 protein. J Agric Food Chem 59:6765-6775.
27. Katagiri Y, Hozumi Y, Kondo S. 2006. Knockdown of SKP2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J Dermatol Sci 42:215-224.
28. Lin SX, Chen J, Mazumdar M, Poirier D, Wang C, Azzi A, Zhou M. 2010. Molecular therapy of breast cancer: Progress and future directions. Nat Rev Endocrinol 6:485-493.
29. Liu J, Wei XL, Huang WH, Chen CF, Bai JW, Zhang GJ. 2012. Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas. PLoS ONE 7:e52675.
30. Malumbres M, Barbacid M. 2001. To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer 1:222-31.
31. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. 2008. PIM kinases promote cell cycle progression by phosphorylating and down-regulating p27KIP1 at the transcriptional and posttranscriptional levels. Cancer Res 68:5076-5085.
32. Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y. 2004. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. J Clin Oncol 22:4165-4173.
33. Park JH, Arakawa-Takeuchi S, Jinno S, Okayama H. 2011. Rho-associated kinase connects a cell cycle-controlling anchorage signal to the mammalian target of rapamycin pathway. J Biol Chem 286:23132-23141.
34. Penin RM, Fernandez-Figueras MT, Puig L, Rex J, Ferrandiz C, Ariza A. 2002. Over-expression of p45(SKP2) in Kaposi's sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27(KIP1) down-regulation. Mod Pathol 15:1227-1235.
35. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature 406:747-752.
36. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO. 2009. Triple-negative breast cancer: Distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2302-2310.
37. Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G. 2008. p27 and SKP2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Ann Oncol 19:660-668.
38. Rico-Bautista E, Yang CC, Lu L, Roth GP, Wolf DA. 2010. Chemical genetics approach to restoring p27KIP1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol 8:153.
39. Shapira M, Kakiashvili E, Rosenberg T, Hershko DD. 2006. The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit SKP2 in breast cancer cells. Breast Cancer Res 8:R46.
40. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M. 2002. Oncogenic role of the ubiquitin ligase subunit SKP2 in human breast cancer. J Clin Invest 110:633-641.
41. Slotky M, Shapira M, Ben-Izhak O, Linn S, Futerman B, Tsalic M, Hershko DD. 2005. The expression of the ubiquitin ligase subunit CKS1 in human breast cancer. Breast Cancer Res 7:R737-R744.
42. Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M. 2006. Significance of SKP2 expression in primary breast cancer. Clin Cancer Res 12:1215-1220.
43. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastle T, Elsen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874.
44. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, Krek W. 1999. p45SKP2 promotes p27KIP1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1:207-214.
45. Totary-Jain H, Sanoudou D, Dautriche CN, Schneller H, Zambrana L, Marks AR. 2012. Rapamycin resistance is linked to defective regulation of SKP2. Cancer Res 72:1836-1843.
46. 1 cyclin-CDK protein kinase activity, is related to p21. Cell 78:67-74.
47. Traub F, Mengel M, Luck HJ, Kreipe HH, von Wasielewski R. 2006. Prognostic impact of SKP2 and p27 in human breast cancer. Breast Cancer Res Treat 99:185-191.
48. Turk CM, Fagan-Solis KD, Williams KE, Gozgit JM, Smith-Schneider S, Marconi SA, Otis CN, Crisi GM, Anderton DL, Kilimann MW, Arcaro KF. 2012. Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers. Cancer Cell Int 12:17.
49. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Köchli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P. 2002. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161:1991-1996.
50. Vervoorts J, Luscher B. 2008. Post-translational regulation of the tumor suppressor p27(KIP1). Cell Mol Life Sci 65:3255-3264.
51. Voduc D, Nielsen TO, Cheang MC, Foulkes WD. 2008. The combination of high Cyclin E and SKP2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Hum Pathol 39:1431-1437.
52. Zhang H, Kobayashi R, Galaktionov K, Beach D. 1995. p19Skp1 and p45SKP2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 82:915-925.
53. Zheng WQ, Zheng JM, Ma R, Meng FF, Ni CR. 2005. Relationship between levels of SKP2 and p27 in breast carcinomas and possible role of SKP2 as targeted therapy. Steroids 70:770-774.